Cancer Drug

• The U.S. Food and Drug Administration (FDA) has approved a new daily pill developed by Revolution Medicines for the treatment of pancreatic cancer. • This groundbreaking medication introduces a novel therapeutic approach to combat one of the most lethal forms of cancer. • The approval is significant as it provides patients with a new targeted option for managing a disease known for its high mortality rate and limited treatment efficacy.

• The US Food and Drug Administration (FDA) has granted expedited approval to daraxonrasib, a first-of-a-kind oral medication designed to treat the most common form of pancreatic cancer. • Developed by Revolution Medicines, the drug functions as a Ras multiselective inhibitor, targeting specific genetic drivers of the disease. • This approval is significant because it provides patients with a more effective treatment option for one of the deadliest types of cancer, which often has limited therapeutic alternatives.

• The FDA has approved a landmark drug designed to treat pancreatic cancer, one of the deadliest forms of the disease. • The medication utilizes a new therapeutic approach by blocking a specific protein that fuels tumor growth in the vast majority of pancreatic cancer cases. • This approval is significant because the drug has demonstrated a measurable ability to improve patient survival rates.

FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancerThe US Food and Drug Administration (FDA) approved a groundbreaking new drug for the most common form of pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases. It’s an approach that has eluded drugmakers for decades. Continue reading...

Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee saysGet our breaking news email, free app or daily news podcastThe federal government should fund treatment for thousands of women with breast cancer or endometriosis, and children with gender dysphoria, according to the Pharmaceutical Benefits Scheme’s advisory committee.The committee met urgently in July in response to AstraZeneca’s announcement it would remove Zoladex from the market, risking leaving more than 7,500 women with breast cancer without an alternative treatment. Continue reading...

• Early-stage research indicates that GLP-1 medications, including Ozempic, Wegovy, Zepbound, and Mounjaro, may reduce the risk of developing certain cancers. • Data shows that patients with liver, breast, colorectal, or lung cancer using these drugs were 38% to 50% less likely to progress to stage 4 disease. • Experts caution that current findings are based on observational studies, which analyze existing data and are less conclusive than controlled clinical trials.

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pillA London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect.Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS), when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...